Pharmaceutical and biotech veterans agreed that partnership between companies is the best approach to sustaining innovation in drug development amid generic competition and financial pressure. To reduce the risk of investing in compounds that might not be successful, drug developers are learning to "experiment with a growing range of new tools and approaches to weed out unpromising drug candidates earlier, speed development and reduce development costs," said Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development.

Related Summaries